Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 6/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9708034 | 0.93 | PDE5A (0.40) | PDE5AADORA3AGTR1AGTR2KMT2A | |
| SCHEMBL9708421 | 0.92 | AGTR1 (0.38) | PDE5AADORA3AGTR1AGTR2KMT2A | |
| SCHEMBL9708670 | 0.92 | KMT2A (0.40) | AGTR1AGTR2KMT2A | |
| SCHEMBL9707993 | 0.92 | ADORA3 (0.42) | ADORA3AGTR1AGTR2KMT2AADORA2A | |
| SCHEMBL9708383 | 0.92 | PDE5A (0.39) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9708346 | 0.91 | KMT2A (0.42) | AGTR1AGTR2KMT2A | |
| SCHEMBL9707948 | 0.90 | AGTR1 (0.38) | AGTR1AGTR2KMT2A | |
| SCHEMBL9708185 | 0.89 | PDE5A (0.41) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9707734 | 0.89 | AGTR1 (0.37) | AGTR1AGTR2KMT2A | |
| SCHEMBL9708328 | 0.89 | PDE5A (0.40) | PDE5AADORA3AGTR1AGTR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992007852-A1 | BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |